Jubilee Post News & Views
The unaudited financial statements for the Q3FY25 results have been released by Supriya Lifescience Ltd., a cGMP-compliant business with a strong track record in API manufacturing and a focus on products from a variety of therapeutic segments, including anti-histamine, anti-allergic, vitamin, anaesthetic, and anti-asthmatic. The company has spread its business in more than 86 countries across the globe.
In the third quarter of FY25, Supriya Lifescience Ltd. witnessed remarkable growth in its revenue, reporting a 33% year-over-year increase, reaching Rs. 185.65 crore compared to Rs. 140.07 crore in Q3 FY24.
Gross Profit for Q3 FY25 stood at Rs. 123.87 crore, with a growth of 45% compared to Rs. 85.45 crore in Q3 FY24.
EBITDA for Q3 FY25 stood at Rs. 65.95 crore, with an EBITDA Margin of 35.50%, as opposed to an EBITDA of Rs. 41.49 crore in Q3 FY24 with an EBITDA margin of 29.60%. This marks an improvement of 591 bps YoY.
The Profit After Tax (PAT) increased by 57% for Q3 FY25 to Rs 46.78 crore, compared to Rs 29.78 crore in Q3 FY24.
The PAT Margin stood at 25.2% in Q3 FY25, compared to 21.30% in Q3 FY24.
Dr. Satish Wagh, Chairman and Whole Time Director, Supriya Lifescience Ltd, commenting on the results, said, “Our Q3FY25 results underscore Supriya Lifescience’s commitment to delivering value through operational excellence and strategic growth initiatives. The 33% year-over-year revenue growth and a remarkable 45% surge in gross profit reflect our strong market presence and efficient execution across therapeutic segments.
The steady improvement in our EBITDA and PAT margins, reaching 35% and 25% respectively, highlights our ability to maintain profitability while investing in sustainable growth.”
.
